SAN DIEGO , Sept. 05, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that

SAN DIEGO , Aug. 29, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that

SAN DIEGO , Aug. 01, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced

-Orphan Drug Designation Program offers potentially up to seven years of marketing exclusivity- -NDA Submission Planned for Fourth Quarter of 2019- SAN DIEGO , July 23, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and

SAN DIEGO , June 28, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that

- Treatment with LJPC-401 Resulted in Statistically Significant Reduction in Change in Transferrin Saturation (TSAT), the Primary Efficacy Endpoint of the Study, and Frequency of Phlebotomies, a Key Secondary Efficacy Endpoint of the Study - SAN DIEGO , June 06, 2019 (GLOBE NEWSWIRE) -- La Jolla

SAN DIEGO, CA - May 6, 2019 - La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for

-Designation offers potential for expedited development and review, and highlights the urgent need for additional treatment options for patients suffering from severe malaria- - NDA Planned for LJPC-0118 for Fourth Quarter of 2019 - SAN DIEGO , April 24, 2019 (GLOBE NEWSWIRE) -- La Jolla

SAN DIEGO , March 11, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the

SAN DIEGO , March 07, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that

SAN DIEGO , March 04, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced

SAN DIEGO , Feb. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it

New Data on GIAPREZA™ (angiotensin II) to be Presented in Oral Sessions at the Society of Critical Care Medicine’s 48th Critical Care Congress SAN DIEGO , Feb. 14, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that there will be multiple presentations on

- Fourth-Quarter 2018 Net Sales of GIAPREZA Were Approximately $4.2 Million , Up 20% from the Third Quarter of 2018 - - Full-Year 2019 Net Sales Guidance for GIAPREZA of $24 Million to $28 Million - - Decision on GIAPREZA MAA by EMA Expected in June of 2019 - - NDA Planned for New Investigational

SAN DIEGO , Jan. 04, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that